Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORSE THREE
NCT04516278Phase 3Completed
- Sponsor
- Outlook Therapeutics
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab in age-related macular degeneration (AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO), sponsored by Outlook Therapeutics. Primary endpoint: Number of Participants With Adverse Events at 3 months. Started Oct 2020; status: completed.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)diabetic macular edema (DME)branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT04516278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516278.